Trial Profile

Phase II Trial of Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 24 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Interleukin-15 (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use

Most Recent Events

31 Mar 2022 Status changed from completed to discontinued. This study was terminated early due to manufacturer withdrawal of support (study medication)due to lack of enrollment.
18 Sep 2021 Status changed from recruiting to completed.
27 May 2020 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jun 2020 to 2 Jun 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com